| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5288726 | COSETTE | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation |
Apr, 2017
(7 years ago) | |
|
US5288726 (Pediatric) | COSETTE | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation |
Oct, 2017
(6 years ago) | |
| US6693115 | COSETTE | Acid addition salts of hydropyridine derivatives |
Jul, 2021
(2 years ago) | |
| US8404703 | COSETTE | Medicinal compositions containing aspirin |
Mar, 2022
(2 years ago) | |
| US8569325 | COSETTE | Method of treatment with coadministration of aspirin and prasugrel |
Jan, 2023
(1 year, 4 months ago) | |
|
US8569325 (Pediatric) | COSETTE | Method of treatment with coadministration of aspirin and prasugrel |
Jul, 2023
(10 months ago) | |
|
US8404703 (Pediatric) | COSETTE | Medicinal compositions containing aspirin |
Jul, 2023
(10 months ago) | |
Effient is owned by Cosette.
Effient contains Prasugrel Hydrochloride.
Effient has a total of 7 drug patents out of which 7 drug patents have expired.
Expired drug patents of Effient are:
- US5288726
- US5288726*PED
- US6693115
- US8404703
- US8569325
- US8569325*PED
- US8404703*PED
Effient was authorised for market use on 10 July, 2009.
Effient is available in tablet;oral dosage forms.
Effient can be used as use of prasugrel and aspirin in patients requiring the reduction of thrombotic cardiovascular events, treatment or prophylaxis of thrombosis or embolisms.
Drug patent challenges can be filed against Effient from 12 January, 2019.
The generics of Effient are possible to be released after 02 July, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-182) | Jul 12, 2019 |
| Pediatric Exclusivity(PED) | Jan 12, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jul 10, 2014 |
Drugs and Companies using PRASUGREL HYDROCHLORIDE ingredient
NCE-1 date: 12 January, 2019
Market Authorisation Date: 10 July, 2009
Treatment: Treatment or prophylaxis of thrombosis or embolisms; Use of prasugrel and aspirin in patients requiring the reduction of thrombotic cardiovascular events
Dosage: TABLET;ORAL
EFFIENT family patents
